Biosimilars Report Bolsters IGBA’s Calls To Streamline Development Process
IPRP Biosimilars Working Group Urges Reassessment Of Comparative Efficacy Studies
Executive Summary
The IGBA has renewed calls to streamline biosimilar development by reducing comparative clinical studies and using the same comparator product across international jurisdictions, citing the findings of a recent publication by the International Pharmaceutical Regulators Programme’s Biosimilars Working Group.